A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CAM-DR / cell adhesion-mediated drug resistance

[Related PubMed/MEDLINE]
Total Number of Papers: 99
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CAM-DR  (>> Co-occurring Abbreviation)
Long Form:   cell adhesion-mediated drug resistance
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 Mechanisms of Cell Adhesion Molecules in Endocrine-Related Cancers: A Concise Outlook. CAMs
2022 PI3K Targeting in Non-solid Cancer. ALL, BM, CLL
2022 Significance of a tumor microenvironment-mediated P65-miR-30a-5p-BCL2L11 amplification loop in multiple myeloma. BMSCs, MM
2022 Targeting CAM-DR and Mitochondrial Transfer for the Treatment of Multiple Myeloma. MM, MM niche, TNTs
2022 Transformable ECM Deprivation System Effectively Suppresses Renal Cell Carcinoma by Reversing Anoikis Resistance and Increasing Chemotherapy Sensitivity. DOX, ECM, EDS, FN, RCC
2021 Cadherins, Selectins, and Integrins in CAM-DR in Leukemia. AML, B- and T-ALL, CAMs, ECM
2021 CAM-DR: Mechanisms, Roles and Clinical Application in Tumors. ECM
2021 Extracellular Matrix Proteins Confer Cell Adhesion-Mediated Drug Resistance Through Integrin alpha v in Glioblastoma Cells. ECM, EGFR, GBM, MDR1, TF
2021 In vitro and in vivo effects of AVA4746, a novel competitive antagonist of the ligand binding of VLA-4, in B-cell acute lymphoblastic leukemia. ALL, VCAM-1
10  2021 The expression of heat shock protein A12B (HSPA12B) in non-Hodgkin's lymphomas. BMSCs, FN, HSPA12B, NHL
11  2020 ANXA7 promotes the cell cycle, proliferation and cell adhesion-mediated drug resistance of multiple myeloma cells by up-regulating CDC5L. ANXA7, CDC5L, CDK1, MM, PCNA
12  2020 beta1-Integrin binding to collagen type 1 transmits breast cancer cells into chemoresistance by activating ABC efflux transporters. ABC, COL1, FN, ITGB1
13  2020 CD49d and CD49e induce cell adhesion-mediated drug resistance through the nuclear factor-kappaB pathway in Burkitt lymphoma. Bax, Bcl-xL, Bim, BL, NF-kappaB
14  2020 Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors. BMM, BMSCs, ECM, EM-DR, SM-DR
15  2020 Effect of Wenxia Changfu Formula Combined With Cisplatin Reversing Non-Small Cell Lung Cancer Cell Adhesion-Mediated Drug Resistance. NSCLC, WCF
16  2020 Elucidating the expression and function of Numbl during cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (MM). Co-IP, MM, PTB
17  2020 Oroxylin A reversed Fibronectin-induced glioma insensitivity to Temozolomide by suppressing IP3R1/AKT/beta-catenin pathway. FN, TMZ
18  2020 Runt-related transcription factor 2 influences cell adhesion-mediated drug resistance and cell proliferation in B-cell non-Hodgkin's lymphoma and multiple myeloma. B-NHL, MM
19  2020 Upregulated expression and function of the alpha4beta1 integrin in multiple myeloma cells resistant to bortezomib. BM, BTZ, ITGB1, MM, OS, PFS, PIs
20  2020 VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival. MMC, V-CP, V-NP, VLA4
21  2020 [Toll-like receptor CD180 and the bone marrow microenvironment as therapeutic targets in multiple myeloma]. BM, EZH2, LPS, MM
22  2019 BTK induces CAM-DR through regulation of CXCR4 degradation in multiple myeloma. BTK, ECM, MM
23  2019 EPHB6 mutation induces cell adhesion-mediated paclitaxel resistance via EPHA2 and CDH11 expression. CDH11, FAK, JNK
24  2019 miR-182 contributes to cell adhesion-mediated drug resistance in multiple myeloma via targeting PDCD4. MM
25  2019 Silencing of LIMD1 promotes proliferation and reverses cell adhesion-mediated drug resistance in non-Hodgkin's lymphoma. LIMD1, NHL
26  2019 Targeting PI3K Signaling in Acute Lymphoblastic Leukemia. ALL, CLL
27  2019 The Impact of Integrin-Mediated Matrix Adhesion on Cisplatin Resistance of W1 Ovarian Cancer Cells. ILK, ITGB1
28  2018 Mechanisms of Matrix-Induced Chemoresistance of Breast Cancer Cells-Deciphering Novel Potential Targets for a Cell Sensitization. COL1, MX
29  2018 [MicroRNA-138 regulates cell adhesion-mediated drug resistance phenotype by targeting SGTA in non-Hodgkin's lymphoma]. FN, NHL, SGTA
30  2017 ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR). ARF1, FN, MM
31  2017 CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma. BM, BMSCs, MM
32  2017 SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. FAK, MCL
33  2017 The PI3Kdelta Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL. ALL, FDA
34  2017 Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphoma. NHL
35  2016 Cell adhesion induces overexpression of chromodomain helicase/ATPase DNA binding protein 1-like gene (CHD1L) and contributes to cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma cells. CHD1L, FN, MM
36  2016 Coadministration of the FNIII14 Peptide Synergistically Augments the Anti-Cancer Activity of Chemotherapeutic Drugs by Activating Pro-Apoptotic Bim. ECM
37  2016 DIXDC1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) via enhancing p-Akt in Non-Hodgkin's lymphomas. DIXDC1, FN, NHL
38  2016 Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. BMSCs, HDACs
39  2016 Epigenetic regulation of cell adhesion-mediated drug resistance acquisition in multiple myeloma. ---
40  2016 Expression of vaccinia-related kinase 1 (VRK1) accelerates cell proliferation but overcomes cell adhesion mediated drug resistance (CAM-DR) in multiple myeloma. MM, VRK1
41  2016 Microenvironment drug resistance in multiple myeloma: emerging new players. DR, MM, SFM-DR
42  2016 Notch1 controls cell chemoresistance in small cell lung carcinoma cells. KD, SCLC
43  2016 RBQ3 participates in multiple myeloma cell proliferation, adhesion and chemoresistance. BMSCs, MM
44  2016 Silencing of CKIP-1 promotes tumor proliferation and cell adhesion-mediated drug resistance via regulating AKT activity in non-Hodgkin's lymphoma. CKIP-1, NHL
45  2016 The cancer cell adhesion resistome: mechanisms, targeting and translational approaches. CAM-RR
46  2016 The role of the Chaperonin containing t-complex polypeptide 1, subunit 8 (CCT8) in B-cell non-Hodgkin's lymphoma. CCT8, CCT8, NHL, RLH
47  2016 The role of ubiquitin-specific protease 14 (USP14) in cell adhesion-mediated drug resistance (CAM-DR) of multiple myeloma cells. MM, USP14
48  2016 Y-box-binding protein-1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma. DLBCL, FN, YB-1
49  2015 Cell adhesion down-regulates the expression of vacuolar protein sorting 4B (VPS4B) and contributes to drug resistance in multiple myeloma cells. MM, VPS4B
50  2015 ENO1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphomas. ENO1, NHLs
51  2015 Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer. EOC, HE4, IHC, OS, PFS
52  2015 Overexpression of TRIP6 promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR) via regulating nuclear p27(Kip1) expression in non-Hodgkin's lymphoma. FN, NHL, TRIP6
53  2015 Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. Bcl-2, HIF1A
54  2015 Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance. MM, PKM2
55  2015 Sam68 regulates cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) via the AKT pathway in non-Hodgkin's lymphoma. CCK-8, NHL
56  2015 Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma. NHL
57  2015 Upregulation of nuclear transporter, Kpnbeta1, contributes to accelerated cell proliferation- and cell adhesion-mediated drug resistance (CAM-DR) in diffuse large B-cell lymphoma. DLBCL, Kpnbeta1
58  2015 [The mechanisms of drug resistance via the interaction of myeloma cells with stromal cells]. ---
59  2014 Expression of small glutamine-rich TPR-containing protein A (SGTA) in Non-Hodgkin's Lymphomas promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR). NHL, SGTA
60  2014 Focal adhesion signaling and therapy resistance in cancer. CAM-RR, ECM
61  2014 Gastric cancer cell adhesion to laminin enhances acquired chemotherapeutic drug resistance mediated by MGr1-Ag/37LRP. ECM
62  2014 Histamine-releasing factor/translationally controlled tumor protein plays a role in induced cell adhesion, apoptosis resistance and chemoresistance in non-Hodgkin lymphomas. DLBCL, FL, FN, HRF, NHLs, NK
63  2014 Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. BM, miR, MM, MSCs, ND
64  2014 MGr1-Ag/37LRP induces cell adhesion-mediated drug resistance through FAK/PI3K and MAPK pathway in gastric cancer. ---
65  2014 Overexpression of fibronectin confers cell adhesion-mediated drug resistance (CAM-DR) against 5-FU in oral squamous cell carcinoma cells. ECM, FN, OSCC
66  2014 Role of integrin alpha4 in drug resistance of leukemia. ALL, BM, MRD
67  2013 Adhesion to fibronectin induces p27(Kip1) nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesion-mediated drug resistance (CAM-DR) in RPMI 8,226 cells. FN
68  2013 Cell adhesion to fibronectin down-regulates the expression of Spy1 and contributes to drug resistance in multiple myeloma cells. FN, MM, MRD
69  2013 Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. ATRA, HA
70  2012 Extracellular matrix proteins modulate antimigratory and apoptotic effects of Doxorubicin. EMDR, SFM-DR
71  2012 Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo. DOX, MM, VLA-4
72  2012 Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma. BM, ECM, FN, MM, VCAM-1
73  2011 Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance. CAM-AR
74  2011 Hammada scoparia flavonoids and rutin kill adherent and chemoresistant leukemic cells. ---
75  2011 Integrin beta7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. FAK, ITGB7, MM
76  2010 Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta(1)-integrin in K562 chronic myelogenous leukemia cell line. BMSCs, CML
77  2009 Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. FN, IL, MM, STAT3
78  2009 ERK/MAPK activation involves hypoxia-induced MGr1-Ag/37LRP expression and contributes to apoptosis resistance in gastric cancer. ERK, MAPK
79  2008 ANTI-ADHESION evolves to a promising therapeutic concept in oncology. CAM
80  2008 Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. CXCR4, ICAM-1, MM, shRNA
81  2008 HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. FN, HSPs, MM
82  2008 Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. ECM, GBM
83  2007 Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. AML, FN, MRD, VLA
84  2007 The association of up-regulation of X-linked inhibitor of apoptosis protein with cell adhesion-mediated drug resistance in U937 cells. AML, FN, PI3K, XIAP
85  2007 Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism. ---
86  2007 [Exploratory study of novel leukemia bone marrow stromal cell adhesion mediated drug resistance model]. BMSC
87  2006 Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. ---
88  2006 Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. AML
89  2006 Tumor microenvironment and drug resistance in hematologic malignancies. EM-DR, SM-DR
90  2004 The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. BMSCs, Fpp, FTase, GGPP, GGTase, HMG-CoA, LFA-1, VLA-4
91  2003 Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. NF-kappaB
92  2003 Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. ---
93  2003 The tumor microenvironment: focus on myeloma. ECM
94  2002 Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. ---
95  2001 Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. CML, ECM, FN
96  2001 The tumor microenvironment as a determinant of drug response and resistance. IL-6
97  2000 Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). ECM, FN
98  2000 Integrin-mediated drug resistance in multiple myeloma. FN
99  1999 Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. FN